» Articles » PMID: 32926263

Femoral Vein Wall Thickness Measurement May Be a Distinctive Diagnostic Tool to Differentiate Behçet's Disease with Intestinal Involvement and Crohn's Disease

Overview
Journal Dig Dis Sci
Specialty Gastroenterology
Date 2020 Sep 14
PMID 32926263
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Backgrounds: Behçet's disease (BD) and Crohn's disease (CD) cannot be easily differentiated in young adults presenting with nonspecific gastrointestinal (GI) manifestations due to similar extraintestinal manifestations. We recently showed that increased common femoral vein (CFV) thickness is a distinctive feature of BD, rarely present in other inflammatory or vascular diseases with a specificity higher than 80% for the cutoff value of ≥ 0.5 mm. We suggest that CFV thickness measurement with ultrasonography (US) can be a diagnostic tool for BD.

Aims: To assess the diagnostic performance of CFV thickness measurement in the differential diagnosis of BD and CD.

Methods: Patients with BD (n = 69), CD (n = 38), and healthy controls (HC) (n = 38) were included in the study. Bilateral CFV thickness was measured with Doppler US.

Results: Both right and left CFV thicknesses were significantly higher in BD compared to HC and CD (for right: 0.76 mm vs 0.33 mm, for left: 0.78 mm vs 0.35 mm, p < 0.001 for both). CFV thicknesses in CD were similar to HC (p > 0.05 for both). CFV thickness was also similar between BD patients with and without GI involvement (p = 0.367). The diagnostic cutoff values of ≥ 0.5 mm for CFV thickness performed well against to both CD and HCs for discrimination of BD. The sensitivity and specificity rates were > 85% for both HC and CD. Positive and negative predictive values in our tertiary clinical setting were > 90%.

Conclusion: We found significantly lower CFV thickness in CD compared to BD. Our results suggest that CFV wall thickness measurement is a distinctive diagnostic tool for the differentiation of BD and CD and can be helpful in daily practice for the differentiation of two diseases.

Citing Articles

[Update on Behçet syndrome].

Kotter I, Ruffer N, Krusche M Z Rheumatol. 2024; 83(10):822-828.

PMID: 39354126 DOI: 10.1007/s00393-024-01576-x.


Measuring the Whole Wall Thickness of the Common Femoral Vein as a Distinctive Diagnostic Tool to Distinguish Behçet's Disease Presenting with Oral Ulcers from Recurrent Aphthous Stomatitis.

Erturk A, Sarikaya Y, Coskun H, Turan C Diagnostics (Basel). 2023; 13(16).

PMID: 37627964 PMC: 10453469. DOI: 10.3390/diagnostics13162705.


Update on the Diagnosis of Behçet's Disease.

Alibaz-Oner F, Direskeneli H Diagnostics (Basel). 2023; 13(1).

PMID: 36611332 PMC: 9818538. DOI: 10.3390/diagnostics13010041.


Behçet's Syndrome Apart From the Triple Symptom Complex: Vascular, Neurologic, Gastrointestinal, and Musculoskeletal Manifestations. A Mini Review.

Kotter I, Lotscher F Front Med (Lausanne). 2021; 8:639758.

PMID: 33898481 PMC: 8063110. DOI: 10.3389/fmed.2021.639758.

References
1.
Zhang T, Hong L, Wang Z, Fan R, Zhang M, Lin Y . Comparison between Intestinal Behçet's Disease and Crohn's Disease in Characteristics of Symptom, Endoscopy, and Radiology. Gastroenterol Res Pract. 2017; 2017:3918746. PMC: 5470017. DOI: 10.1155/2017/3918746. View

2.
Yilmaz S, Simsek I, Cinar M, Erdem H, Kose O, Yazici Y . Patient-driven assessment of disease activity in Behçet's syndrome: cross-cultural adaptation, reliability and validity of the Turkish version of the Behçet's Syndrome Activity Score. Clin Exp Rheumatol. 2013; 31(3 Suppl 77):77-83. View

3.
Hatemi I, Hatemi G, Celik A, Melikoglu M, Arzuhal N, Mat C . Frequency of pathergy phenomenon and other features of Behçet's syndrome among patients with inflammatory bowel disease. Clin Exp Rheumatol. 2008; 26(4 Suppl 50):S91-5. View

4.
Fresko I, Ugurlu S, Ozbakir F, Celik A, Yurdakul S, Hamuryudan V . Anti-Saccharomyces cerevisiae antibodies (ASCA) in Behçet's syndrome. Clin Exp Rheumatol. 2005; 23(4 Suppl 38):S67-70. View

5.
Esatoglu S, Hatemi I, Ozguler Y, Hatemi G, Uzun H, Celik A . Faecal but not serum calprotectin levels look promising in predicting active disease in Behçet's syndrome patients with gastrointestinal involvement. Clin Exp Rheumatol. 2018; 36(6 Suppl 115):90-96. View